Under what circumstances would you consider obinutuzumab instead of rituximab when treating primary membranous nephropathy?

Obinutuzumab is a Type II fully humanized glycoengineered anti-CD20 monoclonal antibody with marked B-Cell depletion along with greater antibody dependent cytotoxicity when compared to Rituximab.

Currently, its use in 'primary' membranous nephropathy is limited to only refractory cases wherein Rituxi...